Screener
Rigel Pharmaceuticals RIGL Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Cash and cash equivalents | $24,411 | $40,580 |
| Short-term investments | 122,273 | 114,375 |
| Accounts receivable, net | 49,945 | 51,763 |
| Inventories | 11,652 | 11,506 |
| Prepaid and other current assets | 25,746 | 21,942 |
| Total current assets | 234,027 | 240,166 |
| Intangible assets, net | 24,160 | 24,748 |
| Deferred income tax asset | 243,279 | 245,852 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's inventories?
- Rigel Pharmaceuticals (RIGL) reported inventories of $11.65M in Q1 2026.
- How has Rigel Pharmaceuticals's inventories changed year-over-year?
- Rigel Pharmaceuticals's inventories increased by 150.1% year-over-year, from $4.66M to $11.65M.
- What is the long-term trend for Rigel Pharmaceuticals's inventories?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's inventories has grown at a 47.7% compound annual growth rate (CAGR), from $1.64M to $11.51M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about Rigel Pharmaceuticals's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude